Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Neutral on IBM, Raises Price Target to $145

Citigroup analyst Jim Suva maintains IBM (NYSE:IBM) with a Neutral and raises the price target from $140 to $145.

byBenzinga Newsdesk

January 26, 2023

1 minute read

Citigroup analyst Jim Suva maintains IBM (NYSE:IBM) with a Neutral and raises the price target from $140 to $145.

Teva To Start Nationwide Settlement Of Opioid Lawsuits From Next Year: Report

By Vandana Singh

Today, 2:15 AM

Reuters reported that Teva Pharmaceutical Industries Ltd’s (NYSE:TEVA) CEO said the company will finalize the U.S. opioid settlement by the end…

TEVA

RBC Capital Upgrades AGF Management to Sector Perform, Raises Price Target to C$9.5

By Benzinga Newsdesk

Today, 2:15 AM

RBC Capital analyst Geoffrey Kwan upgrades AGF Management (TSX:AGF) from Underperform to Sector Perform and raises the price target from C$7.5 to C$9.5.

TSX:AGF

Needham Downgrades Medtronic to Hold

By Benzinga Newsdesk

Today, 2:15 AM

Needham analyst Mike Matson downgrades Medtronic (NYSE:MDT) from Buy to Hold.

MDT

Cinedigm Issue Corrected Q4 Earnings Report: EPS $(0.01), Up From $(0.05) YoY

By Bill Haddad

Today, 2:15 AM

Consolidated Fourth Quarter Revenue of $16.9 Million Up 104% Over Prior Year Led by Record Streaming Revenue Consolidated Full Year Revenue of $56.1 Million Up 78% Over Prior Year Streaming Revenue Up 108% Over Prior

CIDM

Citigroup Maintains Neutral on IBM, Raises Price Target to $145

Related Posts

Teva To Start Nationwide Settlement Of Opioid Lawsuits From Next Year: Report

RBC Capital Upgrades AGF Management to Sector Perform, Raises Price Target to C$9.5

Needham Downgrades Medtronic to Hold

Cinedigm Issue Corrected Q4 Earnings Report: EPS $(0.01), Up From $(0.05) YoY